Big picture - Why invest in Synairgen plc
Synairgen plc Snapshot
Our BioBank Platform Technology
Synairgen’s advanced human tissue models of respiratory disease
Respiratory research has been hampered by the inability of animal models to truly replicate disease pathology and chronicity, as well as the impact of environmental factors such as viruses, cigarette smoke and other inflammatory agents.
Over the years, Synairgen has accumulated an extensive BioBank comprised of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from well-characterised volunteers with asthma or COPD (and relevant controls). Using this resource, Synairgen has developed a number of advanced tissue models.
These models include:
Synairgen can utilise these models to:
- Discover novel drug targets
- Identify disease-related lesions and underlying molecular mechanisms
- Conduct proof of concept testing and validation of novel drug targets
- Conduct screening assays for novel drug targets and lead target selection
- Provide support for clinical trial activities
Once targets have been validated in the laboratory, Synairgen’s clinical team has the proven experience and capability to design and run appropriate Phase I and II proof of concept clinical trials.
Simon Shaw - Non Executive Chairman
Simon joined Synairgen as executive Chairman on its inception in June 2003 and became non-executive Chairman in October of that year. He is Group Chief Financial Officer of Savills plc.
He was Chief Financial Officer of Gyrus Group PLC from 2003 until its sale to Olympus Corporation in 2008, having previously been Chief Operating Officer of Profile Therapeutics plc between 1998 and 2003. Between 1991 and 1997 he was a corporate financier, latterly at Hambros Bank Limited. He is a chartered accountant.
Richard Marsden - Chief Executive Officer
Richard joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.
Dr Phillip Monk - Chief Scientific Officer
Philip joined Synairgen in October 2006 as Head of Bioscience Development and was appointed to the Board as Chief Scientific Officer in September 2009. Phillip was previously Director of the Respiratory and Inflammation Biology group at Cambridge Antibody Technology ('CAT') and led the scientific development of tralokinumab, an anti-IL-13 antibody being developed for the treatment of severe asthma.
Prior to joining CAT, he worked at Bayer AG within the respiratory disease therapeutic area, focusing on the development of novel therapies for asthma, COPD and cystic fibrosis.
John Ward - Finance Director
John joined Synairgen in October 2004 as Finance Director. From December 1999 to July 2004 he was Chief Financial Officer and Company Secretary of Profile Therapeutics plc and was appointed to the Profile Therapeutics board in March 2003.
From 1996 to 1999 he was Finance Director of Rapid Deployment Group Limited, the UK holding company for the healthcare operations of Ventiv Health, Inc. Prior to joining Rapid Deployment he was a Director of Corporate Finance at Price Waterhouse. He is a chartered accountant.
Iain Buchanan - Non-Executive Director
Iain was appointed as a non-executive director in June 2010 and brings to the company over 40 years of management experience in the pharmaceutical and biotech industries. Most recently he was CEO of NOXXON Pharma AG based in Berlin and previously he was CEO of Novexel S.A. based in Paris. He joined Novexel from Vertex Pharmaceuticals where he established the European affiliate. Prior to Vertex, Iain managed the international licensee business of Cilag AG - a subsidiary of Johnson and Johnson - based in Switzerland. Iain continues to serve as a member of the supervisory board of NOXXON Pharma AG.
Dr Bruce Campbell - Non-Executive Director
Bruce joined Synairgen as a non-executive Director in April 2006. He has 40 years of drug development experience and has developed many drugs in a wide range of indications which are now on the market. He currently acts as a consultant to various companies including Proximagen Limited. Formerly he was Senior VP of International Development at Neurocrine Biosciences, Inc. ('Neurocrine'). Prior to joining Neurocrine he worked for 27 years at Servier (United Kingdom), latterly as Scientific Director. In addition, he has also been a director and European Chairman of the Drug Information Association, a member of the European ICH Safety Working Party and a scientific advisor to IP Group plc. He is a visiting Professor in Pharmacology at King's College, London
Paul Clegg - Non-Executive Director
Paul was appointed as a non-executive director of Synairgen in September 2009. He is Chief Executive Officer of Accsys Technologies PLC, Chairman of Tricoya Technologies Ltd and a non-executive director of Peel Hunt LLP. Paul was previously Managing Director and Chief Executive Officer of Cowen International Limited and director of Cowen Asset Management Limited until June 2008. After over twenty years working in the investment banking industry, Paul joined Accsys Technologies PLC, a UK publicly quoted company in the chemical sector, which has developed the process and the commercial industrialisation of wood acetylation. He has successfully turned around, refinanced and repositioned the company.
Prof. Stephen Holgate CBE- Non-Executive Director
Stephen is a co-founder of Synairgen and was appointed a non-executive director in June 2003. After qualifying in Medicine at Charing Cross Hospital Medical School, London he has pursued an academic career leading to his appointment in 1987 to his current position as Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton. His research interests have been largely focused on the cellular and molecular mechanisms of asthma that has involved use of both epidemiological and genetic approaches. He has published over 1000 papers in peer-reviewed literature.
He is currently: Chairman of the MRC Translational Research Group, Member of the MRC Strategy Board; Member of the Science Europe Medical Science Committee and Horizon 2020 Health Science Panel; Chairman of the European Respiratory Society Scientific Council; Board Chair of the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs); Chairman of Defra’s Hazardous Substances Advisory Committee; Trustee of Cancer Research UK, the British Lung Foundation and The Kennedy Trust for Rheumatology Research; and a scientific board member or advisor to a number of companies, including Amgen, Takeda, Merck, and Novartis. In 2010, he was appointed by the Higher Education Funding Council for England to be the Chair of the Research Excellence Framework (REF2014) Main Panel A covering Medicine, Health and Life Sciences.
|Name of shareholder||Number of ordinary shares||% of share capital|
|Woodford Investment Management||21,091,651||23.1%|
|Southampton Asset Management Limited||3,600,000||
Synairgen plc /
Synairgen Research Ltd
Southampton General Hospital
Tel: +44 (0) 23 8051 2800
Fax: +44 (0)23 8051 2800
Nominated adviser and broker
60 New Broad Street
Tel: +44 (0) 20 7220 0500
Tel: +44(0) 23 8088 1700
Tel: 0871 664 0300
(calls cost 10p a minute plus network extras; lines are open 8.30am to 5.30pm Monday - Friday) or if outside the UK +44 (0) 20 8639 3399
Fasken Martineau LLP
17 Hanover Square
Tel: +44 (0) 20 7917 8500
Consilium Strategic Communications
Tel: +44 (0) 20 3709 5701